Estimating chronic hepatitis C prognosis using transient elastography-based liver stiffness: A systematic review and meta-analysis
Corresponding Author
A. Erman
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
Toronto Health Economics and Technology Assessment Collaborative (THETA), University of Toronto, Toronto, ON, Canada
Correspondence
Aysegul Erman, Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, Toronto General Hospital, Toronto, ON, Canada.
Email: [email protected]
Search for more papers by this authorA. Sathya
School of Medicine, Queen's University, Kingston, ON, Canada
Search for more papers by this authorA. Nam
Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada
Search for more papers by this authorJ. M. Bielecki
Toronto Health Economics and Technology Assessment Collaborative (THETA), University of Toronto, Toronto, ON, Canada
Search for more papers by this authorJ. J. Feld
Toronto Centre for Liver Disease, Sandra Rotman Centre for Global Health, University of Toronto, Toronto, ON, Canada
Search for more papers by this authorH-H. Thein
Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
Search for more papers by this authorW. W. L. Wong
School of Pharmacy, University of Waterloo, Kitchener, ON, Canada
Search for more papers by this authorP. Grootendorst
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
Search for more papers by this authorM. D. Krahn
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
Toronto Health Economics and Technology Assessment Collaborative (THETA), University of Toronto, Toronto, ON, Canada
Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada
Search for more papers by this authorCorresponding Author
A. Erman
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
Toronto Health Economics and Technology Assessment Collaborative (THETA), University of Toronto, Toronto, ON, Canada
Correspondence
Aysegul Erman, Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, Toronto General Hospital, Toronto, ON, Canada.
Email: [email protected]
Search for more papers by this authorA. Sathya
School of Medicine, Queen's University, Kingston, ON, Canada
Search for more papers by this authorA. Nam
Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada
Search for more papers by this authorJ. M. Bielecki
Toronto Health Economics and Technology Assessment Collaborative (THETA), University of Toronto, Toronto, ON, Canada
Search for more papers by this authorJ. J. Feld
Toronto Centre for Liver Disease, Sandra Rotman Centre for Global Health, University of Toronto, Toronto, ON, Canada
Search for more papers by this authorH-H. Thein
Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
Search for more papers by this authorW. W. L. Wong
School of Pharmacy, University of Waterloo, Kitchener, ON, Canada
Search for more papers by this authorP. Grootendorst
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
Search for more papers by this authorM. D. Krahn
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
Toronto Health Economics and Technology Assessment Collaborative (THETA), University of Toronto, Toronto, ON, Canada
Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada
Search for more papers by this authorSummary
Chronic hepatitis C (CHC) is a leading cause of hepatic fibrosis and cirrhosis. The level of fibrosis is traditionally established by histology, and prognosis is estimated using fibrosis progression rates (FPRs; annual probability of progressing across histological stages). However, newer noninvasive alternatives are quickly replacing biopsy. One alternative, transient elastography (TE), quantifies fibrosis by measuring liver stiffness (LSM). Given these developments, the purpose of this study was (i) to estimate prognosis in treatment-naïve CHC patients using TE-based liver stiffness progression rates (LSPR) as an alternative to FPRs and (ii) to compare consistency between LSPRs and FPRs. A systematic literature search was performed using multiple databases (January 1990 to February 2016). LSPRs were calculated using either a direct method (given the difference in serial LSMs and time elapsed) or an indirect method given a single LSM and the estimated duration of infection and pooled using random-effects meta-analyses. For validation purposes, FPRs were also estimated. Heterogeneity was explored by random-effects meta-regression. Twenty-seven studies reporting on 39 groups of patients (N = 5874) were identified with 35 groups allowing for indirect and 8 for direct estimation of LSPR. The majority (~58%) of patients were HIV/HCV-coinfected. The estimated time-to-cirrhosis based on TE vs biopsy was 39 and 38 years, respectively. In univariate meta-regressions, male sex and HIV were positively and age at assessment, negatively associated with LSPRs. Noninvasive prognosis of HCV is consistent with FPRs in predicting time-to-cirrhosis, but more longitudinal studies of liver stiffness are needed to obtain refined estimates.
CONFLICT OF INTEREST
Dr. Feld has received research support from Abbvie, Gilead Sciences, Janssen and Merck, Abbot and Regulus and consulting fees from Abbvie, Gilead Sciences, Janssen and Merck.
Supporting Information
Filename | Description |
---|---|
jvh12846-sup-0001-FigS1.tifimage/tif, 2.5 MB | |
jvh12846-sup-0002-FigS2.tifimage/tif, 1.4 MB | |
jvh12846-sup-0003-TableS1-S11.docxWord document, 680.3 KB |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Wasley A, Alter M. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000; 20: 1-16.
- 2Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997; 26: 62S-65S.
- 3Charlton M, Hepatitis C. Infection in Liver Transplantation. Am J Transplant. 2001; 1: 197-203.
- 4Bonny C, Rayssiguier R, Ughetto S, et al. Medical practices and expectations of general practitioners in relation to hepatitis C virus infection in the Auvergne region. Gastroenterol Clin Biol. 2003; 27: 1021-1025.
- 5Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003; 38: 1449-1457.
- 6Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002; 97: 2614-2618.
- 7Sandrin L, Fourquet B, Hasquenoph J-M, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003; 29: 1705-1713.
- 8Afdhal NH, Nunes D. Evaluation of Liver Fibrosis: A Concise Review. Am J Gastroenterol. 2004; 99: 1160-1174.
- 9Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology. 2009; 49: 1017-1044.
- 10Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. 2008; 134: 1670-1681.
- 11Shaheen AAM, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol. 2007; 102: 2589-2600.
- 12Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005; 128: 343-350.
- 13Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005; 41: 48-54.
- 14Colletta C, Smirne C, Fabris C, et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology. 2005; 42: 838-845.
- 15Arena U, Vizzutti F, Abraldes JG, et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut. 2008; 57: 1288-1293.
- 16Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011; 54: 650-659.
- 17Steadman R, Myers RP, Leggett L, et al. A health technology assessment of transient elastography in adult liver disease. Can J Gastroenterol. 2013; 27: 149-158.
- 18Stebbing J, Farouk L, Panos G, et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol. 2010; 44: 214-219.
- 19Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology. 2011; 140: 1970-1973.
- 20Thein H-H, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008; 48: 418-431.
- 21Yi Q, Wang PP, Krahn M. Improving the accuracy of long-term prognostic estimates in hepatitis C virus infection. J Viral Hepat. 2004; 11: 166-174.
- 22Datz C, Cramp M, Haas T, et al. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut. 1999; 44: 563-567.
- 23Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology. 2011; 53: 325-335.
- 24Pinzani M. Liver Fibrosis in the Post-HCV Era. Semin Liver Dis. 2015; 35: 157-165.
- 25Ponziani FR, Mangiola F, Binda C, et al. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol. 2017; 9: 352-367.
- 26McEwan P, Ward T, Yuan Y, Kim R, L'italien G. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology 2013; 58: 54-64.
- 27Obach D, Yazdanpanah Y, Esmat G, et al. How to Optimize Hepatitis C Virus Treatment Impact on Life Years Saved in Resource-Constrained Countries. Hepatology. 2015; 62: 31-39.
- 28Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14: 135.
- 29Roulot D, Czernichow S, Le Clésiau H, et al. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol. 2008; 48: 606-613.
- 30Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634.
- 31Higgins JP, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, Ltd; 2011.
- 32Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009; 172: 137-159.
- 33Kim SU, Choi GH, Han WK, et al. What are “true normal” liver stiffness values using FibroScan®?: a prospective study in healthy living liver and kidney donors in South Korea. Liver Int. 2010; 30: 268-274.
- 34Marshall AD, Micallef M, Erratt A, et al. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study. Int J Drug Policy. 2015; 26: 984-991.
- 35Lucidarme D, Foucher J, Le Bail B, et al. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology. 2009; 49: 1083-1089.
- 36Swan D, Long J, Carr O, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS. 2010; 24: 753-762.
- 37Tapper EB, Castera L, Afdhal NH. FibroScan (Vibration-Controlled Transient Elastography): Where Does It Stand in the United States Practice. Clin Gastroenterol Hepatol. 2015; 13: 27-36.
- 38Probst A, Dang T, Bochud M, et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression–a systematic review and meta-analysis. J Viral Hepat. 2011; 18: 745-759.
- 39Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349: 825-832.
- 40Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. [Review] [63 refs]. Hepatology. 2002; 36: S47-S56.
- 41Rüeger S, Bochud P-Y, Dufour J-F, et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut. 2015; 64: 1605-1615.
- 42Vispo E, Barreiro P, Del Valle J, et al. Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. Antivir Ther. 2009; 14: 187-193.
- 43Friedrich-Rust M, Ong M-F, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008; 134: 960-974.